Mast cell targeted chimeric toxin can be developed as an adjunctive therapy in colon cancer treatment

Toxins

Volumn 8, Issue 3, 2016, Pages

  Wang, Shan ^a   Li, Linmei ^a   Shi, Renren ^a   Liu, Xueting ^a   Zhang, Junyan ^a   Zou, Zehong ^a   Hao, Zhuofang ^a   Tao, Ailin ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Chimeric toxin; Colon cancer; Fc PE40; Mast cell; Tumor microenvironment

Indexed keywords

HISTAMINE; MAST CELL TARGETED CHIMERIC TOXIN; MITOGEN ACTIVATED PROTEIN KINASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; STAT PROTEIN; TOXIN; UNCLASSIFIED DRUG; BACTERIAL TOXIN; EXOTOXIN; IMMUNOGLOBULIN E RECEPTOR; IMMUNOTOXIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A; VIRULENCE FACTOR;

ADENOCARCINOMA; ANGIOGENESIS; ANIMAL CELL; ARTICLE; CANCER GROWTH; CELL INTERACTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAST CELL; MOUSE; NONHUMAN; PHOSPHORYLATION; PLASMID; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; COLON TUMOR; GENETICS; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

ADP RIBOSE TRANSFERASES; ANIMALS; BACTERIAL TOXINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; EXOTOXINS; IMMUNOTOXINS; MAST CELLS; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, IGE; RHO GTP-BINDING PROTEINS; STAT TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRULENCE FACTORS;

EID: 84961970567     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins8030071     Document Type: Article

References (67)

1. De Visser, K.E.; Eichten, A.; Coussens, L.M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 2006, 6, 24-37. [CrossRef] [PubMed]
2. Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. Cell 2010, 140, 883-899. [CrossRef] [PubMed]
3. Quante, M.; Varga, J.; Wang, T.C.; Greten, F.R. The gastrointestinal tumor microenvironment. Gastroenterology 2013,145, 63-78. [CrossRef] [PubMed]
4. Wood, S.L.; Pernemalm, M.; Crosbie, P.A.; Whetton, A.D. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat. Rev. 2014, 40,558-566. [CrossRef] [PubMed]
5. Riese, D.J.; Cullum, R.L. Epiregulin: Roles in normal physiology and cancer. Semin. Cell Dev. Biol. 2014, 28, 49-56. [CrossRef] [PubMed]
6. Loesch, M.; Chen, G. The p38 mapk stress pathway as a tumor suppressor or more? Front. Biosci. 2008,13, 3581-3593. [CrossRef] [PubMed]
7. Kim, E.K.; Choi, E.J. Pathological roles of mapk signaling pathways in human diseases. Biochim. Biophys. Acta 2010,1802, 396-405. [CrossRef] [PubMed]
8. Zhang, Y.; Yan, W.; Collins, M.A.; Bednar, F.; Rakshit, S.; Zetter, B.R.; Stanger, B.Z.; Chung, I.; Rhim, A.D.; di Magliano, M.P. Interleukin-6 is required for pancreatic cancer progression by promoting mapk signaling activation and oxidative stress resistance. Cancer Res. 2013, 73, 6359-6374. [CrossRef] [PubMed]
9. Taylor, C.A.; Zheng, Q.; Liu, Z.; Thompson, J.E. Role of p38 and jnk mapk signaling pathways and tumor suppressor p53 on induction of apoptosis in response to ad-eif5a1 in a549 lung cancer cells. Mol. Cancer 2013. [CrossRef] [PubMed]
10. Sanders, A.J.; Webb, S.L.; Parr, C.; Mason, M.D.; Jiang, W.G. The type ii transmembrane serine protease, matriptase-2: Possible links to cancer? Anti-Cancer Agents Med. Chem. 2010,10, 64-69. [CrossRef]
11. Chia, C.Y.; Kumari, U.; Casey, P.J. Breast cancer cell invasion mediated by galpha12 signaling involves expression of interleukins-6 and -8, and matrix metalloproteinase-2. J. Mol. Signal. 2014, 9,1. [CrossRef] [PubMed]
12. Lin, M.T.; Lin, B.R.; Chang, C.C.; Chu, C.Y.; Su, H.J.; Chen, S.T.; Jeng, Y.M.; Kuo, M.L. Il-6 induces ags gastric cancer cell invasion via activation of the c-src/rhoa/rock signaling pathway. Int. J. Cancer. 2007,120, 2600-2608. [CrossRef] [PubMed]
13. Geng, Y.; Chandrasekaran, S.; Hsu, J.W.; Gidwani, M.; Hughes, A.D.; King, M.R. Phenotypic switch in blood: Effects of pro-inflammatory cytokines on breast cancer cell aggregation and adhesion. PLoS ONE 2013, 8, 54959. [CrossRef] [PubMed]
14. Gacche, R.N.; Meshram, R.J. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth. Prog. Biophys. Mol. Biol. 2013, 113, 333-354. [CrossRef] [PubMed]
15. Le Guelte, A.; Dwyer, J.; Gavard, J. Jumping the barrier: Ve-cadherin, vegf and other angiogenic modifiers in cancer. Biol. Cell 2011,103, 593-605. [CrossRef] [PubMed]
16. Allavena, P.; Mantovani, A. Immunology in the clinic review series; focus on cancer: Tumour-associated macrophages: Undisputed stars of the inflammatory tumour microenvironment. Clin. Exp. Immunol. 2012, 167,195-205. [CrossRef] [PubMed]
17. Sakurai, H. Targeting of tak1 in inflammatory disorders and cancer. Trends Pharmacol. Sci. 2012,33, 522-530. [CrossRef] [PubMed]
18. Vaiopoulos, A.G.; Papachroni, K.K.; Papavassiliou, A.G. Colon carcinogenesis: Learning from nf-kappab and ap-1. Int. J. Biochem. Cell Biol. 2010, 42,1061-1065. [CrossRef] [PubMed]
19. Quintas-Cardama, A.; Verstovsek, S. Molecular pathways: Jak/stat pathway: Mutations, inhibitors, and resistance. Clin. Cancer Res. 2013,19,1933-1940. [CrossRef] [PubMed]
20. Laveti, D.; Kumar, M.; Hemalatha, R.; Sistla, R.; Naidu, V.G.; Talla, V.; Verma, V.; Kaur, N.; Nagpal, R. Anti-inflammatory treatments for chronic diseases: A review. Inflamm. Allergy Drug Targets 2013,12, 349-361. [CrossRef] [PubMed]
21. Yu, H.; Pardoll, D.; Jove, R. Stats in cancer inflammation and immunity: A leading role for stat3. Nat. Rev. Cancer 2009, 9, 798-809. [CrossRef] [PubMed]
22. Crivellato, E.; Beltrami, C.; Mallardi, F.; Ribatti, D. Paul ehrlich's doctoral thesis: A milestone in the study of mast cells. Br. J. Haematol. 2003,123,19-21. [PubMed]
23. Wedemeyer, J.; Tsai, M.; Galli, S.J. Roles of mast cells and basophils in innate and acquired immunity. Curr. Opin. Immunol. 2000,12,624-631. [CrossRef]
24. Galli, S.J.; Tsai, M. Mast cells in allergy and infection: Versatile effector and regulatory cells in innate and adaptive immunity. Eur. J. Immunol. 2010, 40,1843-1851. [CrossRef] [PubMed]
25. Ali, H. Regulation of human mast cell and basophil function by anaphylatoxins c3a and c5a. Immunol. Lett. 2010,128, 36-45. [CrossRef] [PubMed]
26. Huang, B.; Lei, Z.; Zhang, G.M.; Li, D.; Song, C.; Li, B.; Liu, Y.; Yuan, Y.; Unkeless, J.; Xiong, H.; et al. Scf-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 2008,112,1269-1279. [CrossRef] [PubMed]
27. Kanbe, N.; Tanaka, A.; Kanbe, M.; Itakura, A.; Kurosawa, M.; Matsuda, H. Human mast cells produce matrix metalloproteinase 9. Eur. J. Immunol. 1999,29, 2645-2649. [CrossRef]
28. Crivellato, E.; Finato, N.; Ribatti, D.; Beltrami, C.A. Piecemeal degranulation in human tumour pheochromocytes. J. Anat. 2005, 206, 47-53. [CrossRef] [PubMed]
29. Caruso, R.A.; Ieni, A.; Fedele, F.; Zuccala, V.; Riccardo, M.; Parisi, E.; Parisi, A. Degranulation patterns of eosinophils in advanced gastric carcinoma: An electron microscopic study. Ultrastruct. Pathol. 2005, 29, 29-36. [CrossRef] [PubMed]
30. Theoharides, T.C.; Conti, P. Mast cells: The jekyll and hyde of tumor growth. Trends Immunol. 2004, 25, 235-241. [CrossRef] [PubMed]
31. McNeil, H.P.; Adachi, R.; Stevens, R.L. Mast cell-restricted tryptases: Structure and function in inflammation and pathogen defense. J. Biol. Chem. 2007, 282, 20785-20789. [CrossRef] [PubMed]
32. Coussens, L.M.; Tinkle, C.L.; Hanahan, D.; Werb, Z. Mmp-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000,103, 481-490. [CrossRef]
33. Maltby, S.; Khazaie, K.; McNagny, K.M. Mast cells in tumor growth: Angiogenesis, tissue remodelling and immune-modulation. Biochim. Biophys. Acta 2009,1796,19-26. [CrossRef] [PubMed]
34. Crivellato, E.; Nico, B.; Ribatti, D. Mast cells and tumour angiogenesis: New insight from experimental carcinogenesis. Cancer Lett. 2008, 269,1-6. [CrossRef] [PubMed]
35. Ribatti, D. Mast cells and macrophages exert beneficial and detrimental effects on tumor progression and angiogenesis. Immunol. Lett. 2013,152, 83-88. [CrossRef] [PubMed]
36. Adams, W.J.; Morris, D.L. Short-course cimetidine and survival with colorectal cancer. Lancet 1994, 344, 1768-1769. [CrossRef]
37. Matsumoto, S. Cimetidine and survival with colorectal cancer. Lancet 1995, 346,115. [CrossRef]
38. Matsumoto, S.; Imaeda, Y.; Umemoto, S.; Kobayashi, K.; Suzuki, H.; Okamoto, T. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl lewis-x and sialyl lewis-a epitope expression on tumour cells. Br. J. Cancer 2002, 86,161-167. [CrossRef] [PubMed]
39. Khazaie, K.; Blatner, N.R.; Khan, M.W.; Gounari, F.; Gounaris, E.; Dennis, K.; Bonertz, A.; Tsai, F.N.; Strouch, M.J.; Cheon, E.; et al. The significant role of mast cells in cancer. Cancer Metastasis Rev. 2011, 30, 45-60. [CrossRef] [PubMed]
40. Galinsky, D.S.; Nechushtan, H. Mast cells and cancer—No longer just basic science. Crit. Rev. Oncol. Hematol. 2008, 68,115-130. [CrossRef] [PubMed]
41. Nonomura, N.; Takayama, H.; Nishimura, K.; Oka, D.; Nakai, Y.; Shiba, M.; Tsujimura, A.; Nakayama, M.; Aozasa, K.; Okuyama, A. Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br. J. Cancer 2007, 97, 952-956. [CrossRef] [PubMed]
42. Strouch, M.J.; Cheon, E.C.; Salabat, M.R.; Krantz, S.B.; Gounaris, E.; Melstrom, L.G.; Dangi-Garimella, S.; Wang, E.; Munshi, H.G.; Khazaie, K.; et al. Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin. Cancer Res. 2010,16, 2257-2265. [CrossRef] [PubMed]
43. Goffredo, V.; Gadaleta, C.D.; Laterza, A.; Vacca, A.; Ranieri, G. Tryptase serum levels in patients suffering from hepatocellular carcinoma undergoing intra-arterial chemoembolization: Possible predictive role of response to treatment. Mol. Clin. Oncol. 2013,1, 385-389. [CrossRef] [PubMed]
44. Tan, P.H.; Jayabaskar, T.; Yip, G.; Tan, Y.; Hilmy, M.; Selvarajan, S.; Bay, B.H. P53 and c-kit (cd117) protein expression as prognostic indicators in breast phyllodes tumors: A tissue microarray study. Mod. Pathol. 2005, 18,1527-1534. [CrossRef] [PubMed]
45. Gulubova, M.; Vlaykova, T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J. Gastroenterol. Hepatol. 2009, 24,1265-1275. [CrossRef] [PubMed]
46. Yodavudh, S.; Tangjitgamol, S.; Puangsa-art, S. Prognostic significance of microvessel density and mast cell density for the survival of thai patients with primary colorectal cancer. J. Med. Assoc. Thail. 2008, 91, 723-732.
47. Acikalin, M.F.; Oner, U.; Topcu, I.; Yasar, B.; Kiper, H.; Colak, E. Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas. Dig. Liver Dis. 2005, 37,162-169. [CrossRef] [PubMed]
48. Fishman, A.; Lorberboum-Galski, H. Targeted elimination of cells expressing the high-affinity receptor for ige (fc epsilon ri) by a pseudomonas exotoxin-based chimeric protein. Eur. J. Immunol. 1997, 27, 486-494. [CrossRef] [PubMed]
49. Fishman, A.; Prus, D.; Belostotsky, R.; Lorberboum-Galski, H. Targeted fc2'-3-pe40 chimeric protein abolishes passive cutaneous anaphylaxis in mice. Clin. Exp. Immunol. 2000,119,398-403. [CrossRef] [PubMed]
50. Kruger, P.G.; Bloom, G.D. Structural features of histamine release in rat peritoneal mast cells. A study with toluidine blue. Int. Arch. Allergy Appl. Immunol. 1974, 46, 740-752. [PubMed]
51. Nitta, N.; Aoki, Y.; Isogawa, Y.; Tsuchiya, T.; Kanegasaki, S. Image analysis of mast cell degranulation in a concentration gradient of stimuli formed in the channel between a glass plate and a silicon substrate. Eur. J. Cell Biol. 2009, 88, 541-549. [CrossRef] [PubMed]
52. Kovarikova, P.; Michalova, E.; Knopfova, L.; Bouchal, P. Methods for studying tumor cell migration and invasiveness. Klin. Onkol. 2014, 27 (Suppl. 1), S22-S27. [CrossRef] [PubMed]
53. Hill, P.B.; MacDonald, A.J.; Thornton, E.M.; Newlands, G.F.; Galli, S.J.; Miller, H.R. Stem cell factor enhances immunoglobulin e-dependent mediator release from cultured rat bone marrow-derived mast cells: Activation of previously unresponsive cells demonstrated by a novel elispot assay. Immunology 1996, 87, 326-333. [CrossRef] [PubMed]
54. Oliveira, S.H.; Taub, D.D.; Nagel, J.; Smith, R.; Hogaboam, C.M.; Berlin, A.; Lukacs, N.W. Stem cell factor induces eosinophil activation and degranulation: Mediator release and gene array analysis. Blood 2002, 100, 4291-4297. [CrossRef] [PubMed]
55. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature 2008, 454, 436-444. [CrossRef] [PubMed]
56. Grimbaldeston, M.A.; Pearce, A.L.; Robertson, B.O.; Coventry, B.J.; Marshman, G.; Finlay-Jones, J.J.; Hart, P.H. Association between melanoma and dermal mast cell prevalence in sun-unexposed skin. Br. J. Dermatol. 2004,150, 895-903. [CrossRef] [PubMed]
57. Anuradha, A.; Kiran Kumar Naik, B.; Vijay Srinivas, G.; Devi, R.S.; Puneet, H.K. Incidence of mast cells in oral squamous cell carcinoma: A short study. J. Oncol. 2014. [CrossRef] [PubMed]
58. Rabenhorst, A.; Schlaak, M.; Heukamp, L.C.; Forster, A.; Theurich, S.; von Bergwelt-Baildon, M.; Buttner, R.; Kurschat, P.; Mauch, C.; Roers, A.; et al. Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood 2012,120, 2042-2054. [CrossRef] [PubMed]
59. Ribatti, D.; Crivellato, E. The controversial role of mast cells in tumor growth. Int. Rev. Cell Mol. Biol. 2009, 275,89-131. [PubMed]
60. Marichal, T.; Tsai, M.; Galli, S.J. Mast cells: Potential positive and negative roles in tumor biology. Cancer Immunol. Res. 2013,1, 269-279. [CrossRef] [PubMed]
61. Lakshmi Narendra, B.; Eshvendar Reddy, K.; Shantikumar, S.; Ramakrishna, S. Immune system: A double-edged sword in cancer. Inflamm. Res. 2013, 62, 823-834. [CrossRef] [PubMed]
62. Noguchi, T.; Ritter, G.; Nishikawa, H. Antibody-based therapy in colorectal cancer. Immunotherapy 2013, 5, 533-545. [CrossRef] [PubMed]
63. Keppler-Hafkemeyer, A.; Brinkmann, U.; Pastan, I. Role of caspases in immunotoxin-induced apoptosis of cancer cells. Biochemistry 1998, 37,16934-16942. [CrossRef] [PubMed]
64. Perentesis, J.P.; Waddick, K.G.; Bendel, A.E.; Shao, Y.; Warman, B.E.; Chandan-Langlie, M.; Uckun, F.M. Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor. Clin. Cancer Res. 1997, 3, 347-355. [PubMed]
65. Turcotte, S.; Rosenberg, S.A. Immunotherapy for metastatic solid cancers. Adv. Surg. 2011, 45, 341-360. [CrossRef] [PubMed]
66. Tartour, E.; Sandoval, F.; Bonnefoy, J.Y.; Fridman, W.H. Cancer immunotherapy: Recent breakthroughs and perspectives. Med. Sci. 2011, 27, 833-841.
67. Dalton, D.K.; Noelle, R.J. The roles of mast cells in anticancer immunity. Cancer immunology, immunotherapy. Cancer Immunol. Immunother. 2012, 61,1511-1520. [CrossRef] [PubMed]